CN104302283B - 用于治疗异常肾上腺皮质细胞疾病的化合物和方法 - Google Patents

用于治疗异常肾上腺皮质细胞疾病的化合物和方法 Download PDF

Info

Publication number
CN104302283B
CN104302283B CN201380015269.0A CN201380015269A CN104302283B CN 104302283 B CN104302283 B CN 104302283B CN 201380015269 A CN201380015269 A CN 201380015269A CN 104302283 B CN104302283 B CN 104302283B
Authority
CN
China
Prior art keywords
atr
patient
acid
mice
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380015269.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN104302283A (zh
Inventor
加里·哈默
汤姆·凯尔波拉
拉伊利·凯尔波拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millendo Therapeutics Inc
University of Michigan Ann Arbor
Original Assignee
Millendo Therapeutics Inc
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millendo Therapeutics Inc, University of Michigan Ann Arbor filed Critical Millendo Therapeutics Inc
Priority to CN201610595176.5A priority Critical patent/CN106236741A/zh
Publication of CN104302283A publication Critical patent/CN104302283A/zh
Application granted granted Critical
Publication of CN104302283B publication Critical patent/CN104302283B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380015269.0A 2012-03-22 2013-03-13 用于治疗异常肾上腺皮质细胞疾病的化合物和方法 Active CN104302283B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610595176.5A CN106236741A (zh) 2012-03-22 2013-03-13 用于治疗异常肾上腺皮质细胞疾病的化合物和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261614269P 2012-03-22 2012-03-22
US61/614,269 2012-03-22
PCT/US2013/031068 WO2013142214A1 (en) 2012-03-22 2013-03-13 Compounds and methods for treating aberrant adrenocartical cell disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610595176.5A Division CN106236741A (zh) 2012-03-22 2013-03-13 用于治疗异常肾上腺皮质细胞疾病的化合物和方法

Publications (2)

Publication Number Publication Date
CN104302283A CN104302283A (zh) 2015-01-21
CN104302283B true CN104302283B (zh) 2016-08-24

Family

ID=48014328

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380015269.0A Active CN104302283B (zh) 2012-03-22 2013-03-13 用于治疗异常肾上腺皮质细胞疾病的化合物和方法
CN201610595176.5A Pending CN106236741A (zh) 2012-03-22 2013-03-13 用于治疗异常肾上腺皮质细胞疾病的化合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610595176.5A Pending CN106236741A (zh) 2012-03-22 2013-03-13 用于治疗异常肾上腺皮质细胞疾病的化合物和方法

Country Status (12)

Country Link
US (5) US9107883B2 (enExample)
EP (1) EP2838523A1 (enExample)
JP (2) JP6234987B2 (enExample)
CN (2) CN104302283B (enExample)
AU (2) AU2013235535B2 (enExample)
BR (1) BR112014023517B1 (enExample)
CA (1) CA2867668A1 (enExample)
HK (1) HK1206607A1 (enExample)
IN (1) IN2014DN08604A (enExample)
MX (1) MX355129B (enExample)
NZ (1) NZ630828A (enExample)
WO (1) WO2013142214A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2748238B2 (ja) 1994-12-20 1998-05-06 新興機械工業株式会社 ばね製造装置の足起こし装置
US9107883B2 (en) * 2012-03-22 2015-08-18 Atterocor, Inc. Compounds and methods for treating aberrant adrenocartical cell disorders
US20150087649A1 (en) * 2013-09-26 2015-03-26 Atterocor, Inc. Treating disorders associated with aberrant adrenocortical cell behavior
CN107205941A (zh) * 2014-09-26 2017-09-26 米伦多治疗公司 N‑(2,6‑二(1‑甲基乙基)苯基)‑n′‑((1‑(4‑(二甲基氨基)苯基)环戊基)甲基)脲盐酸盐的固体药物形式以及涉及其的组合物、方法和试剂盒
WO2016164476A2 (en) * 2015-04-06 2016-10-13 Millendo Therapeutics, Inc. Combination therapy for treating disorders associated with excess cortisol production
US20180200209A1 (en) * 2015-07-10 2018-07-19 Millendo Therapeutics, Inc. Enhanced bioavailability of n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)-phenyl)cyclopentyl)methyl)urea hydrochloride
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
US10231983B1 (en) 2018-08-22 2019-03-19 Corcept Therapeutics, Inc. Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
US11202787B2 (en) 2018-07-02 2021-12-21 Corcept Therapeutics, Inc. Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
US10780097B2 (en) 2018-07-02 2020-09-22 Corcept Therapeutics, Inc. Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
US20220241276A1 (en) * 2019-06-11 2022-08-04 The Regents Of The University Of Michigan Compositions and methods for treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009067397A2 (en) * 2007-11-19 2009-05-28 Ore Pharmaceuticals Inc. Treatment for solid tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5015644A (en) 1987-06-02 1991-05-14 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds
NZ577219A (en) * 2006-12-06 2011-11-25 Smithkline Beecham Corp Bicyclic compounds and use as antidiabetics
US9107883B2 (en) * 2012-03-22 2015-08-18 Atterocor, Inc. Compounds and methods for treating aberrant adrenocartical cell disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009067397A2 (en) * 2007-11-19 2009-05-28 Ore Pharmaceuticals Inc. Treatment for solid tumors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Isolation and use of primary adrenocortical cells from guinea pigs,dogs and monkeys for in vitro toxicity studies;Grushenka H.I.Wolfgang等;《Toxicology Methods》;19941231;第4卷(第3期);第150页第3段，第156页第2段 *
Morphogenesis of a Zone-Specific Adrenocortical Cytotoxicity in Guinea Pigs Administered PD 132301-2, an Inhibitor of Acyl-CoA: Cholesterol Acyltransferase;MARK A.DOMINICK等;《Toxicologic Pathology》;19931231;第21卷(第1期);第56页右栏倒数第2段 *

Also Published As

Publication number Publication date
AU2013235535B2 (en) 2017-09-21
US20160367507A1 (en) 2016-12-22
HK1206607A1 (en) 2016-01-15
CN106236741A (zh) 2016-12-21
US9877937B2 (en) 2018-01-30
AU2017261632A1 (en) 2017-12-07
NZ630828A (en) 2016-10-28
AU2013235535A1 (en) 2014-10-09
US20220160662A1 (en) 2022-05-26
US9107883B2 (en) 2015-08-18
US9446010B2 (en) 2016-09-20
CA2867668A1 (en) 2013-09-26
JP6317016B2 (ja) 2018-04-25
IN2014DN08604A (enExample) 2015-05-22
US20160008302A1 (en) 2016-01-14
JP2017160275A (ja) 2017-09-14
US20130267550A1 (en) 2013-10-10
BR112014023517B1 (pt) 2020-12-01
CN104302283A (zh) 2015-01-21
US20180256524A1 (en) 2018-09-13
EP2838523A1 (en) 2015-02-25
MX355129B (es) 2018-04-06
MX2014011188A (es) 2015-03-06
JP2015510933A (ja) 2015-04-13
JP6234987B2 (ja) 2017-11-22
WO2013142214A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
CN104302283B (zh) 用于治疗异常肾上腺皮质细胞疾病的化合物和方法
US20240342122A1 (en) Use of Short Chain Fatty Acids in Cancer Prevention
TWI289449B (en) Compositions and methods for the treatment of cancer
TWI542349B (zh) 利用３－（５－胺基－２－甲基－４－氧基－４ｈ－喹唑啉－３－基）－六氫吡啶－２，６－二酮治療癌症之方法
TWI430793B (zh) 利用免疫調節化合物供治療及管控癌症及其它疾病之方法及組合物
US10973822B2 (en) Combination therapy for treatment of hematological cancers and solid tumors
US20020128228A1 (en) Compositions and methods for the treatment of cancer
ES2940302T3 (es) Métodos para tratar el mieloma múltiple con compuestos inmunomoduladores en combinación con anticuerpos
EP3938368B1 (en) Compound form having enhanced bioavailability and formulations thereof
TW201642857A (zh) 以組合療法治療肝細胞癌
TWI870704B (zh) 治療表達pd-l1之癌症的方法
CN104822369A (zh) 包含穗霉素衍生物的组合物及其使用方法
EP2504703B1 (en) Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells
HK1230524A1 (en) Compounds and methods for treating aberrant adrenocartical cell disorders
HK1230524A (en) Compounds and methods for treating aberrant adrenocartical cell disorders
US20240216465A1 (en) Method for treating refractory brain tumor
TW202428876A (zh) 治療難治型腦瘤之方法
WO2008073304A9 (en) Cancer treatment methods
WO1999004817A1 (en) Chemotherapy synergistic agent

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: michigan

Applicant after: The Regents of the Univ. of Michigan

Applicant after: Milunduo treatment company

Address before: michigan

Applicant before: The Regents of the Univ. of Michigan

Applicant before: ATTEROCOR INC

COR Change of bibliographic data
C14 Grant of patent or utility model
GR01 Patent grant